Literature DB >> 20854627

Ten years of stroke programmes in Poland: where did we start? Where did we get to?

Anna Członkowska1, Maciej Niewada, Iwona Sarzyñska-Długosz, Adam Kobayashi, Marta Skowroñska.   

Abstract

UNLABELLED: Risk factors and a high stroke mortality rate are a heavy stroke burden on Central and Eastern European countries. The 1995 Helsingborg Declaration outlined the aim of the coming decade was to improve patient care. In Poland it led to the foundation of the National Stroke Prevention and Treatment Programme, (1998-2008) which later became part of the National Cardiovascular Disease Prevention and Treatment Programme. THE AIM: • Improve acute and postacute management • Implement innovative therapies • Develop poststroke rehabilitation, and • Monitor epidemiology. Establishing and equipping stroke units has raised their number from three to 111. Thrombolysis for stroke and carotid angioplasty and stenting procedures were supported and supervised. The needs in poststroke rehabilitation were assessed and services have improved due to the support of the programme. Continuous monitoring of patient care proved that the mortality and disability rates have decreased and the quality of treatment has improved.

Entities:  

Mesh:

Year:  2010        PMID: 20854627     DOI: 10.1111/j.1747-4949.2010.00470.x

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  2 in total

1.  Designing the future of thrombectomy in Poland: first we must agree on the principles.

Authors:  Michał Karliński; Adam Kobayashi; Bartosz Karaszewski; Anna Członkowska
Journal:  Postepy Kardiol Interwencyjnej       Date:  2022-05-17       Impact factor: 1.065

2.  Acute Ischemic Stroke Hospital Admissions, Treatment, and Outcomes in Poland in 2009-2013.

Authors:  Kamil Chwojnicki; Danuta Ryglewicz; Bogdan Wojtyniak; Paweł Zagożdżon; Anna Członkowska; Tadeusz Jędrzejczyk; Bartosz Karaszewski; Grzegorz Kozera; Marek Gierlotka; Majid Ezzati; Tomasz Zdrojewski
Journal:  Front Neurol       Date:  2018-03-13       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.